Overview

AMG 761 in Adults With Asthma

Status:
Terminated

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine that no significant safety issues will be identified following a single dose of AMG 761 in asthma subjects that would preclude further development of AMG 761.

Phase:

Phase 1

Details

Lead Sponsor:

Amgen

Treatments:

Mogamulizumab